ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
BCAL DIAGNOSTICS LTD
0.070
-0.001
-1.41%
成交量:
12.56萬
成交額:
8,838
市值:
2,576.47萬
市盈率:
-3.49
高:
0.071
開:
0.071
低:
0.070
收:
0.071
52周最高:
0.155
52周最低:
0.052
股本:
3.68億
流通股本:
2.02億
量比:
2.20
換手率:
0.06%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.020
每股收益(LYR):
-0.020
淨資產收益率:
-273.29%
總資產收益率:
-50.29%
市淨率:
-31.18
市盈率(LYR):
-3.50
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
BCAL Diagnostics澄清:未與GSS或MAP進行任何併購談判或提案往來
美股速递
·
09/10
BCAL Diagnostics:文中所引述言論源自部分主張三方合併的基金管理人之觀點
美股速递
·
09/10
BCAL診斷公司:要求罷免Michael Aicher,並提名Forrester與Melki進入GSS董事會
美股速递
·
09/03
遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情
美股速递
·
09/03
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BDX.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.07,"timestamp":1789537627885,"preClose":0.071,"halted":0,"volume":125576,"delay":0,"changeRate":-0.01408450704225334,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":368067640,"eps":-0.020055,"marketStatus":"Pre CSPA","change":-0.001,"latestTime":"09-16 16:03:09 AEST","open":0.071,"high":0.071,"low":0.07,"amount":8838,"amplitude":0.014085,"askPrice":0.075,"askSize":392,"bidPrice":0.07,"bidSize":15970,"shortable":3,"etf":0,"ttmEps":-0.020055,"tradingStatus":3,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":13,"adr":0,"exchange":"ASX","adjPreClose":0.071,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":2.203041,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BDX.AU","preClose":0.065,"auctionPrice":0.076,"auctionVolume":5071,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020586342}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-50.29%","roe":"-273.29%","lyrEps":-0.02,"volumeRatio":2.203041,"shares":368067640,"dividePrice":0,"high":0.071,"amplitude":0.014085,"preClose":0.071,"low":0.07,"week52Low":0.052,"pbRate":"-31.18","psRate":"10.95","week52High":0.155,"institutionHeld":0,"latestPrice":0.07,"committee":0.952084,"eps":-0.020055,"divideRate":0,"volume":125576,"delay":0,"ttmEps":-0.020055,"open":0.071,"prevYearClose":0.105,"prevWeekClose":0.075,"prevMonthClose":0.066,"prevQuarterClose":0.075,"fiveDayClose":0.065,"twentyDayClose":0.056,"sixtyDayClose":0.073},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"BDX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788393600000,"name":null,"time":"","dateTimestamp":1788357600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126786572","title":"BCAL Diagnostics澄清:未與GSS或MAP進行任何併購談判或提案往來","url":"https://stock-news.laohu8.com/highlight/detail?id=1126786572","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126786572?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:22","pubTimestamp":1789010533,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics发布声明,明确表示该公司既未主动提出、也未曾收到任何并购提案,目前亦未与GSS或MAP就合并事宜或其他形式的联合展开任何讨论。这家诊断企业强调,市场上关于其与上述实体进行潜在交易的传言缺乏事实依据。声明措辞简洁而直接,意在消除外界猜测。BCAL Diagnostics的此番表态,似乎是对近期业内传闻的正面回应——传闻曾暗示该公司可能卷入一场涉及同行业者的整合浪潮之中。这种滴水不漏的措辞,无疑是为了杜绝任何解释上的灰色地带。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180507719","title":"BCAL Diagnostics:文中所引述言論源自部分主張三方合併的基金管理人之觀點","url":"https://stock-news.laohu8.com/highlight/detail?id=1180507719","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180507719?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:21","pubTimestamp":1789010474,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics——此前文章中提及的相关评论,实际反映的是部分基金管理人的个人见解,这些基金管理者长期以来一直积极呼吁推动三方合并事宜。\n需要明确的是,这些观点并非公司官方的正式立场。事实上,那些支持三方合并方案的基金经理们,已在多个场合公开表达过他们的倾向性看法。而文章所引用的言论,恰恰来源于这些在幕后持续推动该议程的机构投资者群体。\n在当前的资本运作讨论中,这一细节值得市场参与者给予充分关注,因为它揭示了潜在的利益相关方对未来公司架构演变的不同期待与设想。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173556031","title":"BCAL診斷公司:要求罷免Michael Aicher,並提名Forrester與Melki進入GSS董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1173556031","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173556031?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:42","pubTimestamp":1788403333,"startTime":"0","endTime":"0","summary":"BCAL诊断有限公司已正式提出动议,要求将Michael Aicher从Genetic Signatures Ltd董事会中罢免。与此同时,该公司还力荐Forrester及Melki两位候选人,以期他们能够顺利加入GSS董事会。这一人事调整举措,无疑为GSS公司的治理结构投下了一枚重磅炸弹。BCAL方面显然希望通过此番运作,重塑董事会的权力格局,注入新鲜血液。BCAL此举的深层动因,以及新任董事若顺利上位后将带来怎样的治理新风,均有待市场的进一步观察与解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BDX.AU","GSS.AU","BK7048","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115211142","title":"遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情","url":"https://stock-news.laohu8.com/highlight/detail?id=1115211142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115211142?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 07:39","pubTimestamp":1788392350,"startTime":"0","endTime":"0","summary":"遗传特征有限公司(Genetic Signatures Ltd, GSS.AU)已正式向BCAL诊断有限公司(BCAL Diagnostics Ltd, BDX.AU)发出请求,要求后者就其在该公司的持股情况以及关联方关系提供更为详尽的说明。\n据悉,此项请求涉及BCAL诊断在遗传特征公司中的股东身份及相关联方细节,但具体交易背景及可能引发的后续影响尚未对外披露。市场参与人士正密切关注事态发展,以评估这一动向可能对两家澳大利亚医疗诊断领域企业带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7048","GSS.AU","BDX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BDX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}